BMS signs ADC development deal with Munich-based biotech worth more than $1B

cafead

Administrator
Staff member
  • cafead   Apr 20, 2023 at 12:02: PM
via BMS will have exclusive access to Tubulius’ proprietary P5 conjugation and Tubutecan platforms to develop customizable ADCs for treating cancer and solid tumors.

article source